Swedish Orphan Biovitrum: Coagulation Protein Disorders trials
The registry lists 10 Coagulation Protein Disorders studies with Swedish Orphan Biovitrum as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 1Phase 3 2Phase 4 2No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaTerminatedNCT05856266Phase 4Results posted
- Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruitingNCT06940830Phase 4
- Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaActive, not recruitingNCT06716814Phase 3
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ACompletedNCT06579144Phase 1
- A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaCompletedNCT05817812Phase 3
- An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia BCompletedNCT03901755
- A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in FranceCompletedNCT03655340
- Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and BCompletedNCT03276130
- A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or BCompletedNCT03055611
- Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor ProductsCompletedNCT02976753